👤 Hossein Ali Ghasemi

Optimizing the use of dietary emulsifiers and prebiotics in relation to fat source may enhance nutrient-utilization efficiency in broiler production. This 42-d study evaluated the effects of an emulsifier (lysophospholipid; LPL) and inulin supplementation in diets with two fat sources on growth performance, nutrient digestibility, muscle fatty acid composition, digestive enzyme activity, and intestinal histomorphology. Eight hundred 1-d-old male broiler chickens were assigned to eight treatments in a 2 × 2 × 2 factorial design with two fat sources (soybean oil or beef tallow), two LPL levels (0 or 1 g/kg), and two inulin levels (0 or 1 g/kg). Interactive effects were detected for fat source × inulin on average daily gain (ADG), mortality, and the European Production Index (EPI), with inulin addition to soybean-oil-based diets yielding superior growth and survival rates (P < 0.05). The LPL × inulin interaction increased feed intake and improved gain-to-feed ratio (P < 0.05). The fat source × LPL interaction significantly influenced lipid-metabolism-related traits (P < 0.05); in tallow-based diets, LPL supplementation increased fat digestibility and AMEn, reduced breast fat deposition, and improved the fatty acid profile of thigh muscle by elevating n-3 PUFA and lowering the n-6/n-3 ratio, whereas no significant effects occurred in soybean-oil-based diets. When interaction terms were not significant, LPL increased protease and lipase activities and improved duodenal villus height and surface area, whereas inulin increased protease activity, improved protein digestibility, and enhanced jejunal villus architecture (P < 0.05). In conclusion, LPL is particularly beneficial in tallow-based diets by enhancing lipid digestibility, energy utilization, and the thigh-muscle fatty acid profile, while inulin improves growth performance, especially in soybean-oil-based diets-offering a practical strategy to optimize broiler production. Show less

This study aimed to investigate the effects of GAA supplementation in diets differing in ME levels on productive performance, egg quality, blood parameters, yolk fatty acid profiles, hepatic expression of genes related to lipid metabolism, gut morphology, and nutrient digestibility in laying hens during their post-peak production phase. Over a 12-week period (52-64 weeks of age), 288 laying hens were randomly assigned to 6 treatments. Each treatment consisted of 8 replicates, with 6 hens per replicate. The experimental treatments were assigned in a 2 × 3 factorial arrangement, comprising 2 levels of dietary ME (a recommended level and a low level, the latter characterized by a 100 kcal/kg reduction in ME) and 3 levels of GAA supplementation (0, 0.6, and 1.2 g/kg). The results showed significant interaction effects (P < 0.05) between GAA supplementation and dietary ME levels on laying rate, egg mass, feed conversion ratio, crude protein digestibility, and AMEn. In hens fed the low-ME diet, GAA supplementation, particularly at 1.2 g/kg, significantly improved laying performance. Moreover, at both 0.6 and 1.2 g/kg under low-ME conditions, GAA significantly enhanced crude protein digestibility and AMEn. The low-ME diet was associated with decreased expression of key lipogenic genes, including sterol regulatory element-binding transcription factor 1 (SREBF1), acetyl-coenzyme A carboxylase (ACC), and fatty acid synthase (FAS), alongside increased expression of genes involved in fatty acid oxidation, such as peroxisome proliferator-activated receptor alpha (PPARα) and carnitine palmitoyltransferase 1 (CPT1). Regardless of ME content, GAA supplementation linearly improved eggshell strength, enhanced the polyunsaturated-to-saturated fatty acid ratio in the yolk, elevated serum levels of creatine and total antioxidant capacity, improved intestinal morphology, and increased radical scavenging activity in the yolk (P < 0.05). Furthermore, GAA supplementation linearly increased the relative mRNA expression of several metabolic genes, including SREBF1, ACC, PPARα, and ApoB (P < 0.05). In conclusion, GAA supplementation enhanced productive performance in low-ME diets and exerted positive effects on egg characteristics and lipid metabolism, regardless of dietary ME content. Show less

This study aims to develop a receptor-dependent 4D-QSAR model to overcome key limitations of traditional QSAR, including its dependency on molecular alignment and poor performance with small datasets, by integrating ligand - target interaction information. Angiogenesis-related receptors, including VEGFR2, FGFR1-4, EGFR, PDGFR, RET, and HGFR (MET) were chosen based on the biological relevance in cancer. Ligand datasets with known IC₅₀ values were extracted from PubChem. One hundred docked conformers per ligand were generated using AutoDock. Protein - ligand interaction fingerprints were computed and encoded as 4D-descriptors. After evaluation via multiple classification algorithms, Random Forest was selected for model construction. The results shown that the proposed model outperformed traditional 2D-QSAR approaches across all targets. Accuracy exceeded 70% in most datasets, including those with fewer than 30 compounds. Besides, the model performance was significantly improved via using all conformers versus using a single best pose. The model demonstrated robust predictive power across varying receptor classes under consistent assay conditions. The proposed receptor-dependent 4D-QSAR model provides enhanced accuracy and generalizability for small, diverse datasets. Its integration of LTI-derived descriptors makes it a valuable tool for early-stage lead optimization and supports rational multi-target drug design in oncology. Show less

Congenital myasthenic syndromes (CMSs) are genetic disorders affecting motor function with variable symptoms. RAPSN-related CMS, caused by mutations in the RAPSN gene, leads to muscle weakness. Accurate diagnosis is essential for proper management. This study aims to analyze six Iranian families affected by RAPSN-CMS, focusing on clinical manifestations, genetic variants, treatment response, and outcomes. Clinical assessments, genetic analysis, and whole-exome sequencing were performed on the six families to identify RAPSN gene mutations. The study examined symptoms, disease severity, age of onset, treatment response, and outcomes. Treatment with pyridostigmine and salbutamol was given to assess its effectiveness. Three homozygous known variants in RAPSN gene were identified: c.491G > A in three families, c.264 C > A in two families, and c.-210 A > G in one family. Clinical assessments showed diversity in symptoms and treatment responses. Pyridostigmine and salbutamol treatment improved symptoms and quality of life. This study highlights the significance of molecular diagnosis for RAPSN-related congenital myasthenic syndromes (CMS) in Iran, marking the first comprehensive genetic analysis in the region. The identification of specific pathogenic variants underscores the unique genetic landscape of local patients. Furthermore, our long-term follow-up revealed variable treatment responses, emphasizing the need for personalized care strategies. The clinical variability among patients with identical mutations necessitates a multidisciplinary approach for effective management. By enhancing genetic awareness and refining follow-up methods, we aim to improve diagnosis accuracy and interventions, fostering better outcomes for affected families in the Iranian population. Show less

Breast cancer is one of the main challenging areas in cancer treatment. Natural compounds such as curcumin and berberine have been approved with anticancer effects and are more favorable to people. Here, we investigated the potential synergistic anticancer effects of these two compounds in combination with the standard cancer drug 5-FU on the growth of MCF-7 breast cancer cells. This study tested the effects of six different treatments on cancer cell growth: A) control; B) curcumin; C) berberine; D) 5-FU; E) curcumin + berberine; and F) curcumin + berberine + 5-FU. The IC There was a reduction in cancer cell growth and invasion, and an increase in cellular decomposition across all treatment groups compared to the control with the strongest effects seen in the combined curcumin/berberine/5-FU group. The expression levels of all tested genes were altered in all treatment groups compared to the control, with that of WNT1, CTNNB1, TCF, MTOR, AKT1, BIRC5, and CCND1 showing the most robust changes in the combined curcumin/berberine/5-FU treatment. All treatment groups had anti-growth, anti-invasion, and pro-apoptotic effects on MCF-7 breast cancer cells in culture. In addition, all treatment groups showed changes in the expression of the genes involved in cancer cell growth and survival with the strongest effects found for the curcumin/berberine/5-FU combination. Therefore, curcumin and berberine may improve the anticancer effects of chemotherapy and these natural compounds should undergo further testing as potential adjuvants. Show less

The HERMES (HEart failure Molecular Epidemiology for Therapeutic targetS) consortium aims to identify the genomic and molecular basis of heart failure. The consortium currently includes 51 studies from 11 countries, including 68 157 heart failure cases and 949 888 controls, with data on heart failure events and prognosis. All studies collected biological samples and performed genome-wide genotyping of common genetic variants. The enrolment of subjects into participating studies ranged from 1948 to the present day, and the median follow-up following heart failure diagnosis ranged from 2 to 116 months. Forty-nine of 51 individual studies enrolled participants of both sexes; in these studies, participants with heart failure were predominantly male (34-90%). The mean age at diagnosis or ascertainment across all studies ranged from 54 to 84 years. Based on the aggregate sample, we estimated 80% power to genetic variant associations with risk of heart failure with an odds ratio of ≥1.10 for common variants (allele frequency ≥ 0.05) and ≥1.20 for low-frequency variants (allele frequency 0.01-0.05) at P < 5 × 10 HERMES is a global collaboration aiming to (i) identify the genetic determinants of heart failure; (ii) generate insights into the causal pathways leading to heart failure and enable genetic approaches to target prioritization; and (iii) develop genomic tools for disease stratification and risk prediction. Show less

Melanoma is a cancer that has a high mortality rate in the absence of targeted therapy. Conventional therapies such as surgery, chemotherapy, and radiotherapy are associated with poor prognosis. The expression of miR-21 appears to be of clinical importance, and the regulation of its expression appears to be an opportunity for treatment. In this current study, we aimed to evaluate the effects of miR-21 inhibition in- vitro and in-vivo. In-vitro studies have investigated LNA-anti-miR-21 in mouse melanoma cells (B16F10), and in-vivo studies have proposed a model of melanoma in male C57BL/6 mice. To evaluate the anticancer effects of LNA-anti-miR-21, a QRT-PCR analysis was performed using the 2 MiR-21 expression was inhibited by 80% after 24 h of B16F10 cell line transfection with LNA-anti-miR-21. The MTT test showed a significant reduction in the number of transfected cells with LNA-anti-miR-21. The transfected cells showed a significant increase in apoptosis in comparison with the control and scrambled LNA groups. According to our in vivo findings, anti-miR-21 could reduce tumor growth and volume in mice receiving intraperitoneal anti-miR after 9 days. The expression of the Show less

Recent genome-wide association studies (GWAS) have identified several genetic variants that influence the risk of dyslipidemia and coronary artery disease (CAD). In this study, we have examined the potential association of five SNPs variants related to lipid pathway, previously identified in GWAS studies (ZNF259 C>G, CETP I405VA/G, LPA C>T, LPLS447X and PSRC1 A>G) with CAD. Two hundred and ninety subjects including 194 patients with coronary artery disease and 96 controls were enrolled, followed by the analyses of anthropometric/biochemical parameters. Genotyping was carried out using Taq-Man real-time PCR based method. The association of the genetic polymorphisms with CAD was determined using univariate and multivariate analyses. CAD patients had a higher (p < 0.05) fasting blood glucose (FBG), total cholesterol (TC), high sensitivity C-reactive protein (hs-CRP), low-density lipoprotein cholesterol (LDL-C) and waist circumference. Results showed that subjects with CETP rs5882 genetic variant, AA&AG genotypes, had a higher risk of developing Coronary artery disease [OR: 2.1, 95% CI (1.2-4.1), p value = 0.015]. Also subjects who carried the G allele of the ZNF259 polymorphism were at an increased the risk of developing CAD [OR 1.86, 95% CI: 1.06-3.25, p value = 0.029] and had an increased TC, LDL and TG levels (p < 0.05). Furthermore, no statistically significant association was found between genetic polymorphisms of PSRC1 A>G, LPL S447X and LPA C>T and CAD. We identified a relationship between a genetic variant in CETP and ZNF259 gene with CAD and CAD and lipid profile, respectively. Further investigation in a larger population may help to investigate the value of emerging marker as a risk stratification marker in CAD and its risk factors. Show less

It is suggested that C771G (His241Gln) polymorphism of MLXIPL gene might be a genetic risk factor for coronary artery disease (CAD); therefore, the aim of the present study was to investigate the association between C771G polymorphism of MLXIPL gene and the pathogenesis of CAD in Iranian patients with coronary artery stenosis and control subjects. Two hundred and five patients with coronary artery stenosis and 195 healthy control subjects were included in this study. MLXIPL genotypes were determined by polymerase chain reaction and restriction fragment length polymorphism (RFLP). There was an association between the MLXIPL polymorphism and quantitative lipid traits in patient group. Distribution of the CC genotype of MLXIPL was more frequent in patients, (χ2=5.13; p<0.005) and after adjustment for classical CAD risk factors, the MLXIPL CC genotype was independently associated with CAD (OR=1.98, 95% CI, 1.12-4.11; p=0.02). Distribution of MLXIPL genotypes were significantly different as compared with the severity of stenosis (χ2=6.34; p<0.05). These results suggest that C771G polymorphism of MLXIPL gene is associated with stenosis and its severity. Show less

In a recent study, a genome-wide scan has identified C771G (His241Gln) polymorphism of MLX interacting protein like (MLXIPL) gene that is associated with the level of plasma triglycerides. Since, no study has been reported on the association between MLXIPL gene and non-alcoholic fatty liver disease (NAFLD), we aimed to identify a connection between this genetic variation and NAFLD. Two hundred and thirteen patients with NAFLD and 252 healthy controls were entered into this study. MLXIPL genotypes were determined by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP). Our study showed that the single nucleotide polymorphism (SNP) of MLXIPL is significantly associated with NAFLD. Significant differences between cases and controls were observed for MLXIPL genotype frequencies (p<0.002). The frequency of C allele of MLXIPL in patient group was higher than the control group (68.30% vs. 51.59%, respectively; p<0.05). C771G polymorphism in the MLXIPL gene potentially plays a significant role in pathophysiology of non-alcoholic fatty liver disease. Further research is needed to confirm this finding. Show less

Lactococcus garvieae is an emerging pathogen responsible for lactococcosis, a serious disease in trout aquaculture. The identification of new bacteriophages against L. garvieae strains may be an effective way to fight this disease and to study the pathogen's biology. Three L. garvieae phages, termed WP-1, WWP-2 and SP-2, were isolated from different environments, and their morphological features, genome restriction profiles and structural protein patterns were studied. Random cloning of HindIII-cut fragments was performed, and the fragments were partially sequenced for each phage. Although slight differences were observed by transmission electron microscopy, all of the phages had hexagonal heads and short non-contractile tails and were classified as members of the family Podoviridae. Restriction digestion analysis of the nucleic acids of the different phages revealed that the HindIII and AseI digests produced similar DNA fragment patterns. Additionally, SDS-PAGE analysis indicated that the isolated phages have similar structural proteins. The sequence BLAST results did not show any significant similarity with other previously identified phages. To the best of our knowledge, this study provides the first molecular characterization of L. garvieae phages. Show less

Nitric oxide (NO) mediates a substantial part of its physiologic functions via S-nitrosylation, however the cellular substrates for NO-mediated S-nitrosylation are largely unknown. Here we describe the S-nitrosoproteome using a high-density protein microarray chip containing 16,368 unique human proteins. We identified 834 potentially S-nitrosylated human proteins. Using a unique and highly specific labeling and affinity capture of S-nitrosylated proteins, 138 cysteine residues on 131 peptides in 95 proteins were determined, defining critical sites of NO's actions. Of these cysteine residues 113 are novel sites of S-nitrosylation. A consensus sequence motif from these 834 proteins for S-nitrosylation was identified, suggesting that the residues flanking the S-nitrosylated cysteine are likely to be the critical determinant of whether the cysteine is S-nitrosylated. We identify eight ubiquitin E3 ligases, RNF10, RNF11, RNF41, RNF141, RNF181, RNF208, WWP2, and UBE3A, whose activities are modulated by S-nitrosylation, providing a unique regulatory mechanism of the ubiquitin proteasome system. These results define a new and extensive set of proteins that are susceptible to NO regulation via S-nitrosylation. Similar approaches could be used to identify other post-translational modification proteomes. Show less